Literature DB >> 21240591

[Pulmonary affection in advanced liver disease - hepatepulonary syndrome and portopulmonary hypertension].

Kerstin Herzer1, Felix Post, Ali Canbay, Guido Gerken.   

Abstract

Patients suffering from severe chronic liver disease, in particular cirrhosis, are at risk for pulmonary complications. The leading clinical symptom is shortness of breath, which can accompany the actual disease as indirect effect because of anemia, faint muscles or ascites. On the other hand, dyspnea can have multiple additive causes in case of accompanying cardial or pulmonary disease. The hepatopulmonary syndrome (HPS) and the portopulmonary hypertension (PoPH) belong to the most relevant pulmonary complications in liver cirrhosis. HPS appears to be more common than PoPH and the presence of either entity increases morbidity and mortality in patients with liver disease. The two diseases have to be strictly distinguished, as they have opposed histological and pathophysiological origin. While the HPS is a dilatative pulmonary- vascular disease, the PoPH is a constrictive or obliterative pulmonary-vascular disease in the context of a liver disease or a portal hypertension. Therefore, these diseases are separate entities also when it comes to diagnostics and therapy.

Entities:  

Mesh:

Year:  2011        PMID: 21240591     DOI: 10.1007/s00063-010-1157-9

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  77 in total

1.  Portopulmonary hypertension: diagnostic advances and caveats.

Authors:  Michael J Krowka
Journal:  Liver Transpl       Date:  2003-12       Impact factor: 5.799

Review 2.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

3.  Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome.

Authors:  H M Lasch; M W Fried; S L Zacks; P Odell; M W Johnson; D A Gerber; F S Sandhu; J H Fair; R Shrestha
Journal:  Liver Transpl       Date:  2001-02       Impact factor: 5.799

4.  Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Authors:  Peter Schenk; Maximilian Schöniger-Hekele; Valentin Fuhrmann; Christian Madl; Gerd Silberhumer; Christian Müller
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

5.  Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue.

Authors:  M J Krowka; E R Dickson; D A Cortese
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

6.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

7.  Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.

Authors:  Michael J Krowka; M Susan Mandell; Michael A E Ramsay; Steve M Kawut; Michael B Fallon; Cosme Manzarbeitia; Manuel Pardo; Paul Marotta; Shinji Uemoto; Markus P Stoffel; Joanne T Benson
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

8.  Experience with inhaled iloprost and bosentan in portopulmonary hypertension.

Authors:  M M Hoeper; H J Seyfarth; G Hoeffken; H Wirtz; E Spiekerkoetter; M W Pletz; T Welte; M Halank
Journal:  Eur Respir J       Date:  2007-07-25       Impact factor: 16.671

Review 9.  Improvement of hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: case report and review of literature.

Authors:  Anil S Paramesh; Sohail Z Husain; Benjamin Shneider; Jeffrey Guller; Ikbal Tokat; Gabriel E Gondolesi; Susan Moyer; Sukru Emre
Journal:  Pediatr Transplant       Date:  2003-04

10.  Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.

Authors:  Mercedes Fernandez; Francesco Vizzutti; Juan Carlos Garcia-Pagan; Juan Rodes; Jaime Bosch
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.